Clinical trial · Observational
Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer
Multicenter Real-world Clinical Study of Inetetamab-based Therapy in HER2-positive Metastatic Breast Cancer
NCT06305702CI-TRIAL-00074947completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023. The study aimed to estimate the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) associated with inetetamab therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HER2-positive Metastatic Breast Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| inetetamab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression Free Survival(PFS)
- timeFrame
- 12 months
Secondary outcomes (2)
- measure
- objective response rate (ORR)
- timeFrame
- 12 months
- measure
- Adverse events (AEs)
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. An age of at least 18 years or older 2. Pathologically diagnosed with HER2-positive recurrent or metastatic breast cancer 3. Having at least one measurable lesion as defined 4. Receiving inetetamab-based therapy in the recurrent or metastatic stage 5. Having traceable medical history records Exclusion Criteria: 1. Pregnant or lactating women 2. Patients with other conditions deemed unsuitable for participating in this study by the researcher
References
Publications (0)
Data not yet available
No reference posted for this study.